2024-10-09
Fushine Pharmaceuticals signed a technology transfer cooperation agreement with Jiangxi Normal University to upgrade its processes to achieve cost reduction and efficiency improvement.
This newspaper (Reporter Cao Qi) reports that on October 8th, the sweet fragrance of osmanthus filled the air. A grand signing ceremony for the technology achievement transformation between Jiangxi Fushine Pharmaceutical Co., Ltd. ("Fushine Pharmaceuticals") and Jiangxi Normal University (Jiangxi Normal University) was held in Jingdezhen, Jiangxi Province. Chen Fener, an academician of the Chinese Academy of Engineering and president of Jiangxi Normal University, and Wang Yong, a member of the Education Working Committee of the Jiangxi Provincial Party Committee and deputy director of the Education Department, attended the ceremony.
In this cooperation, Fushine Pharmaceuticals will give full play to its industrial advantages in the field of biopharmaceuticals, combine with the scientific research strength of Jiangxi Normal University, and jointly promote the transformation and application of scientific research results, so as to enable the company's products to achieve intelligent and continuous production, thereby improving production safety, reducing production costs, and enhancing the overall competitiveness of the company's products.
In fact, this research achievement has been translated into the industrialization of a fully continuous enzymatic asymmetric synthesis process for key intermediates in the penem series of antibacterial drugs. Bao Jianhua, Chairman of Fushine Pharmaceuticals, stated, "The penem series is a class of atypical β-lactam high-end antibiotics primarily used to treat serious bacterial infections. It is one of the company's key product lines, accounting for nearly one-third of the company's major pharmaceutical product revenue. As an industry-leading supplier of the high-end antibiotic penem series, our greatest expectation and confidence lies in optimizing the production process of key intermediates in the penem series of antibacterial drugs using a fully continuous enzymatic asymmetric synthesis process. This innovation will significantly improve production efficiency and is expected to reduce the cost of key penem intermediates by 15% to 20%."
Fushine Pharmaceuticals primarily engages in the research, development, production, and sale of active pharmaceutical ingredients and intermediates for anti-infective drugs. Leveraging its shared technological expertise, the company is expanding into the application areas of chemical and biological synthesis, focusing on developing lithium battery electrolyte additives and expanding its synthetic biology microbial protein business. Facing fierce market competition in recent years, the company has continuously innovated to strengthen its core competitiveness. The penem product line is one of the company's key product lines, accounting for nearly one-third of its revenue from major pharmaceutical-related products. Its process upgrades are therefore crucial to the company as a whole.
Furthermore, fully continuous flow technology significantly improves production safety. "For chemical companies, safe production is paramount. Fushine Pharmaceuticals has always prioritized corporate social responsibility, and we will continue to strive to serve society and benefit the people!" said Bao Jianhua. "We firmly believe that over the next one to two years, leveraging these technological innovations, we will continue to consolidate and enhance our leading position in the penicillin product market."
It is worth noting that this cooperation is also an active connection between the two parties to Jiangxi's "1269 Action Plan", targeting major scientific issues and key core technologies, overcoming difficulties to integrate disciplinary resources and talent advantages, and striving to lead industrial innovation with scientific and technological innovation, and more proactively and accurately serve the high-quality development of Jiangxi's pharmaceutical industry chain, helping Jiangxi to accelerate the construction of a modern industrial system, and jointly promote the construction of Jiangxi as an important measure for a strong industrial province.
(Editor Zhang Mingfu)
In this cooperation, Fushine Pharmaceuticals will give full play to its industrial advantages in the field of biopharmaceuticals, combine with the scientific research strength of Jiangxi Normal University, and jointly promote the transformation and application of scientific research results, so as to enable the company's products to achieve intelligent and continuous production, thereby improving production safety, reducing production costs, and enhancing the overall competitiveness of the company's products.
In fact, this research achievement has been translated into the industrialization of a fully continuous enzymatic asymmetric synthesis process for key intermediates in the penem series of antibacterial drugs. Bao Jianhua, Chairman of Fushine Pharmaceuticals, stated, "The penem series is a class of atypical β-lactam high-end antibiotics primarily used to treat serious bacterial infections. It is one of the company's key product lines, accounting for nearly one-third of the company's major pharmaceutical product revenue. As an industry-leading supplier of the high-end antibiotic penem series, our greatest expectation and confidence lies in optimizing the production process of key intermediates in the penem series of antibacterial drugs using a fully continuous enzymatic asymmetric synthesis process. This innovation will significantly improve production efficiency and is expected to reduce the cost of key penem intermediates by 15% to 20%."
Fushine Pharmaceuticals primarily engages in the research, development, production, and sale of active pharmaceutical ingredients and intermediates for anti-infective drugs. Leveraging its shared technological expertise, the company is expanding into the application areas of chemical and biological synthesis, focusing on developing lithium battery electrolyte additives and expanding its synthetic biology microbial protein business. Facing fierce market competition in recent years, the company has continuously innovated to strengthen its core competitiveness. The penem product line is one of the company's key product lines, accounting for nearly one-third of its revenue from major pharmaceutical-related products. Its process upgrades are therefore crucial to the company as a whole.
Furthermore, fully continuous flow technology significantly improves production safety. "For chemical companies, safe production is paramount. Fushine Pharmaceuticals has always prioritized corporate social responsibility, and we will continue to strive to serve society and benefit the people!" said Bao Jianhua. "We firmly believe that over the next one to two years, leveraging these technological innovations, we will continue to consolidate and enhance our leading position in the penicillin product market."
It is worth noting that this cooperation is also an active connection between the two parties to Jiangxi's "1269 Action Plan", targeting major scientific issues and key core technologies, overcoming difficulties to integrate disciplinary resources and talent advantages, and striving to lead industrial innovation with scientific and technological innovation, and more proactively and accurately serve the high-quality development of Jiangxi's pharmaceutical industry chain, helping Jiangxi to accelerate the construction of a modern industrial system, and jointly promote the construction of Jiangxi as an important measure for a strong industrial province.
(Editor Zhang Mingfu)
